Aignostics Jobs and more

Aignostics: Pioneer in AI-supported Precision Medicine

About Aignostics

Aignostics is a global artificial intelligence (AI) company specializing in transforming complex multimodal pathology data into transformative insights. Founded in 2018 as a spin-off of Charité – Universitätsmedizin Berlin and the Berlin Institute of Health, Aignostics is headquartered in Berlin with a branch in New York.

Key Products and Services

edit

Aignostics develops AI-based solutions for pathology that are based on a proprietary "Explainable AI" platform. This platform, which is based on research from the Fraunhofer Society, Charité, and TU Berlin, aims to overcome the "black box" problem of AI in pathology. The company's activities include the development of customized algorithms for research and diagnostics, particularly in the areas of drug discovery, translational research, clinical trials, and the development of companion diagnostics (CDx)[2][3].

Mission and Values

edit

The mission of Aignostics is to transform drug development and improve patient outcomes through innovative solutions for precision medicine. The company relies on a combination of proprietary access to multimodal clinical data, industry-leading technologies, and rigorous scientific methodology to develop top-notch products and services. Transparency and diligence in the application of AI models are core values that strengthen the trust of biopharmaceutical customers and the scientific community[1][3].

Sustainability Goals and Initiatives

edit

Aignostics is strongly committed to promoting medical innovations and focuses on sustainable and responsible practices. The company has developed a GCP-ready clinical trial platform that is certified under the standards of ISO 13485 (Quality Management System) and ISO/IEC 27001 (Information Security Management System). These certifications guarantee the highest standards regarding quality and data security[3].

Recent Developments

edit

Aignostics recently completed a Series B funding round of $34 million to develop new product offerings for biopharmaceutical customers, promote growth in the USA, and develop leading foundational models for pathology in collaboration with the Mayo Clinic. This funding underscores investors' confidence in the differentiated AI models and the company's clear business strategy[1].

Recognitions and Partnerships

edit

Aignostics was recently included in the ranking of "World's Best Digital Health Companies 2024" by Newsweek, highlighting its leading role in the diagnostics category. The company works closely with renowned partners such as the Mayo Clinic, Bayer, and other biopharmaceutical companies to advance precision medicine[1][4].

With an interdisciplinary team of over 100 experts with deep roots in pathology and machine learning and a global presence in Berlin and New York, Aignostics positions itself as a pioneer in AI-supported precision diagnostics and medicine.

Sources:

edit